Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Operating Leases (2021 - 2025)

Capricor Therapeutics has reported Operating Leases over the past 5 years, most recently at $14.3 million for Q4 2025.

  • Quarterly results put Operating Leases at $14.3 million for Q4 2025, up 2223.55% from a year ago — trailing twelve months through Dec 2025 was $14.3 million (up 2223.55% YoY), and the annual figure for FY2025 was $14.3 million, up 2223.55%.
  • Operating Leases for Q4 2025 was $14.3 million at Capricor Therapeutics, down from $14.4 million in the prior quarter.
  • Over the last five years, Operating Leases for CAPR hit a ceiling of $14.4 million in Q3 2025 and a floor of $194603.0 in Q2 2025.
  • Median Operating Leases over the past 5 years was $1.7 million (2023), compared with a mean of $3.0 million.
  • Peak annual rise in Operating Leases hit 2223.55% in 2025, while the deepest fall reached 81.36% in 2025.
  • Capricor Therapeutics' Operating Leases stood at $2.5 million in 2021, then dropped by 23.43% to $1.9 million in 2022, then dropped by 20.83% to $1.5 million in 2023, then crashed by 58.55% to $616315.0 in 2024, then surged by 2223.55% to $14.3 million in 2025.
  • The last three reported values for Operating Leases were $14.3 million (Q4 2025), $14.4 million (Q3 2025), and $194603.0 (Q2 2025) per Business Quant data.